Facebook
Twitter
LinkedIn
ForwardMonthly Oncology Tumor Boards (June 2018 - May 2019)
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a set of step-by step evidence-based, consensus-driven recommendations to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patient’s preferences when applying the guidelines to ensure optimal care for the individual. The multidisciplinary team discusses how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines® to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the guidelines might be best applied.
NCCN will offer a series of twelve multidisciplinary case-based webinars on the management of patients with various cancer types: acute myeloid leukemia, B-cell lymphomas, bladder cancer, brain cancer, breast cancer, colorectal cancer, hepatocellular carcinoma, melanoma, multiple myeloma, non-small cell lung cancer, ovarian cancer, and renal cell carcinoma.
Target Audience
This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Learning Objectives
The goal of this project is to ensure that members of the multidisciplinary oncology team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the management of patients with various cancer types.
- Review new, emerging and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
- Communicate the importance of a multidisciplinary approach in the management of patients with cancer.
All live webinars in this series are complete.
The recorded webcasts from this series are listed below:
- Brain Cancer: Multidisciplinary Teamwork in Guiding Treatment Decisions and Management of Patients Undergoing Surgery or Radiation for Intracranial Tumors (presented on Friday, June 29, 2018, by Ian Parney, MD, PhD, and Paul Brown, MD, Mayo Clinic Cancer Center)
- Bladder Cancer: Advances in the Treatment of Muscle-Invasive Bladder Cancer (presented on Wednesday, July 25, 2018, by Thomas Pugh, MD, and Thomas Flaig, MD, University of Colorado Cancer Center)
- Breast Cancer: Management of HR-Sensitive, HER2-Negative Advanced Breast Cancer (presented on Tuesday, August 28, 2018, by Melinda Telli, MD, and Jessica Foran, NP, Stanford Cancer Institute)
- Ovarian Cancer: Sequencing Therapy for Patients with Ovarian Cancer (presented on Tuesday, September 25, 2018, by Jennifer G. Filipi, MSN, NP, and Richard T. Penson, MD, MRCP, Massachusetts General Hospital Cancer Center)
- Non-Small Cell Lung Cancer: Novel Targeted Therapies and Immunotherapies for Metastatic NSCLC (presented on Thursday, October 25, 2018, by Sandip Patel, MD, and Grace Lin, MD, PhD, UC San Diego Moores Cancer Center)
- Melanoma: Primary and Adjuvant Treatment for Stage III Disease (presented on Friday, December 7, 2018, by Daniel G. Coit, MD, and Alexander N. Shoushtari, MD, Memorial Sloan Kettering Cancer Center)
- Renal Cell Carcinoma (RCC): Management of RCC (presented on Friday, December 21, 2018, by Elizabeth R. Plimack, MD, MS, and Robert G. Uzzo, MD, Fox Chase Cancer Center)
- Hepatocellular Carcinoma (HCC): Management of Advanced HCC (presented on Tuesday, January 22, 2019, by Stacey M. Stein, MD, and Mario Strazzabosco, MD, PhD from Yale Cancer Center/Smilow Cancer Hospital)
- Acute Myeloid Leukemia (AML): Novel and Emerging Treatment Options for AML (presented on Tuesday, February 19, 2019, by Martin S. Tallman, MD, and Bernadette Cuello, AOCNP, NP, Memorial Sloan Kettering Cancer Center)
- Colorectal Cancer: Emerging Approaches to Personalized Medicine in Colorectal Cancer (presented on Thursday, April 18, 2019, by Jeffrey Meyerhardt, MD, MPH, Dana-Farber Cancer Institute, and Jonathan A. Nowak, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center)
- Multiple Myeloma: Management of Multiple Myeloma (presented on Monday, May 20, 2019, by Natalie S. Callander, MD and Michelle L. Lakner, MSN, APNP, University of Wisconsin Carbone Cancer Center)
- B-Cell Lymphomas: Diagnosis and Treatment of Diffuse Large B-Cell Lymphomas (DLBCL) (presented on Wednesday, May 29, 2019, by Andrew D. Zelenetz, MD, PhD and Jason T. Carter, PA-C, MPH, Memorial Sloan Kettering Cancer Center)
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Full disclosure of faculty relationships will be made prior to the activity.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals for both the live webinars and recorded webcasts. NCCN will also seek approval for case manager clock hours for the live webinars only. Complete accreditation information is provided before each individual educational activity.
Price
Please refer to the Schedule tab for dates and times. Check the webinars you would like to attend and click Enroll.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing